Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Michael C. Lowe, Ragini R. Kudchadkar
Publikováno v:
Surgical Oncology Clinics of North America. 29:445-453
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promisin
Autor:
Alan L. Ho, Johanna C. Bendell, Daniel D. Von Hoff, Ragini R. Kudchadkar, Valerie Andre, Ramon V. Tiu, Les H. Brail, Jeffrey R. Infante, Trevor Tucker, Celine Pitou, Michael R. Migden
Publikováno v:
Clinical Cancer Research. 24:2082-2091
Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe administration to patients with locally advanced/metastatic cancer. Experimental Design: This was a phase I, multicenter, o
Publikováno v:
American Society of Clinical Oncology Educational Book. :661-672
There has been a therapeutic revolution in the treatment of metastatic melanoma over the past decade. Patients presenting with inoperable disease have several therapeutic options, which can include both targeted and immune therapy. Immune checkpoint
Autor:
Ahmad A. Tarhini, Ragini R. Kudchadkar
Publikováno v:
Cancer treatment reviews. 71
The treatment armamentarium for patients with metastatic melanoma has increased substantially over the past decade with the regulatory approval of targeted BRAF + MEK inhibitors and immune checkpoint inhibitors, which have vastly improved long-term o
Publikováno v:
Current Problems in Cancer. 38:180-198
In recent years, the oncologic community has witnessed monumental strides in the management of solid tumors using molecular data and targeted therapies. There are 2 prototypical solid tumors that exemplify the molecular renaissance: lung adenocarcino
Autor:
Susan N. Thomas, Brian Pollack, Gregory B. Lesinski, Yun Min Chang, Maiko Sasaki, Edmund K. Waller, Anna E. Kersh, Haydn T. Kissick, Spencer Ng, Ragini R. Kudchadkar
Publikováno v:
Journal of clinical pharmacology. 58(1)
Two pharmacologic approaches that are currently at the forefront of treating advanced cancer are those that center on disrupting critical growth/survival signaling pathways within tumor cells (commonly referred to as "targeted therapies") and those t
Autor:
Geoffrey T. Gibney, Ragini R. Kudchadkar, Alexander R. A. Anderson, Vernon K. Sondak, Silvya Stuchi Maria-Engler, Renato Ramos Massaro, Jane L. Messina, Eunjung Kim, Inna V. Fedorenko, Ravi K. Amaravadi, Vito W. Rebecca, Keiran S.M. Smalley
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
This study investigates the mechanism of action behind the long-term responses (12–16 months) of two BRAF WT melanoma patients to the AKT inhibitor MK-2206 in combination with paclitaxel and carboplatin. Although single agent MK-2206 inhibited phos
Autor:
James S. Trimble, Keiran S.M. Smalley, Ragini R. Kudchadkar, Vernon K. Sondak, L. Frank Glass
Publikováno v:
Clinics in Dermatology. 31:200-208
Since the discovery of activating mutations in the BRAF oncogene in melanoma, there has been remarkable progress in the development of targeted therapies for unresectable and metastatic melanoma. We review the latest developments in our understanding
Autor:
Ricardo J. Gonzalez, Geoffrey T. Gibney, Leslie M. Turner, Ragini R. Kudchadkar, Keiran S.M. Smalley, Timothy W. McCardle, Jacob J. Benedict, Sarah Sloot, Vernon K. Sondak, Jonathan S. Zager, Jeffrey S. Weber, Jane L. Messina, R. C. DeConti
Publikováno v:
Melanoma Research, 26(1), 83-87. LIPPINCOTT WILLIAMS & WILKINS
Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16d38f31c0846b2de9e11dd6e633516
https://research.rug.nl/en/publications/e7053d76-4bbe-428d-9d29-4187e5918d44
https://research.rug.nl/en/publications/e7053d76-4bbe-428d-9d29-4187e5918d44
Publikováno v:
Cancer control : journal of the Moffitt Cancer Center. 20(4)
The previous 2 years have been an exciting time in melanoma research, due in part to the approval of vemurafenib and ipilimumab for advanced melanoma. Increased knowledge of the molecular biology leading to melanoma has led to the development of seve